A nurse is reinforcing teaching about the management of hyperthyroidism during pregnancy to a client who has the condition.
Which of the following statements should the nurse reinforce in the teaching?

Choice B rationale

Magnesium sulfate is a central nervous system depressant and is the primary medication used for seizure prophylaxis in clients with preeclampsia with severe features. It acts by decreasing acetylcholine release at the neuromuscular junction and producing vasodilation. The goal is to prevent the progression of preeclampsia to eclampsia, which is characterized by the onset of grand mal seizures. Therapeutic magnesium levels for this purpose are generally maintained between 4 to 7 mEq/L.

Choice A rationale

A biophysical profile is an ultrasound assessment of fetal well-being that measures fetal breathing, movements, tone, amniotic fluid volume, and heart rate reactivity. While magnesium sulfate is used to treat the mother, its primary purpose is not to improve the BPP score. In fact, high levels of magnesium can sometimes cause a temporary decrease in fetal heart rate variability or fetal breathing movements, potentially leading to a lower BPP score even if the fetus is stable.

Choice C rationale

Placental abruption is a serious complication where the placenta detaches from the uterus before delivery. While preeclampsia increases the risk of abruption due to vascular damage and high blood pressure, magnesium sulfate is not administered specifically to prevent the abruption itself. Its pharmacological action is focused on the neurological system to prevent seizures. Management of abruption risk involves blood pressure control and close monitoring of maternal symptoms and fetal heart rate patterns.

Choice D rationale

Although magnesium sulfate has a mild vasodilatory effect, it is not classified as an antihypertensive medication and is not used for the primary purpose of decreasing blood pressure. If a client's blood pressure exceeds 160/110 mmHg, specific antihypertensive agents such as labetalol or hydralazine are administered. The role of magnesium is strictly for the prevention of eclamptic seizures in the setting of severe preeclampsia. Monitoring for magnesium toxicity involves checking deep tendon reflexes.

Choice A rationale

Referral to a diabetes mellitus educator is not a standard or necessary part of hyperthyroidism management unless the client also has a concurrent diagnosis of diabetes. While both are endocrine disorders, their management strategies are entirely different. Hyperthyroidism focuses on regulating thyroid hormone production and cardiac symptoms, whereas diabetes focuses on glucose monitoring and insulin sensitivity. Therefore, this referral would be inappropriate and irrelevant for a client specifically seeking help for hyperthyroidism.

Choice B rationale

Management of hyperthyroidism during pregnancy is complex and requires specialized knowledge to balance maternal health with fetal safety. Endocrinologists are experts in hormonal regulation and are best equipped to manage medications like propylthiouracil or methimazole, which carry specific risks at different gestations. Collaborative care between the obstetrician and an endocrinologist ensures that thyroid levels are maintained in the high-normal range to avoid fetal hypothyroidism while preventing maternal thyrotoxicosis or thyroid storm.

Choice C rationale

Hyperthyroidism does not necessarily resolve after giving birth. In fact, many clients with Graves' disease may experience a significant flare-up or "rebound" of symptoms in the postpartum period as the immune system recovers from the pregnancy-induced state of suppression. While some temporary forms of gestational thyrotoxicosis might subside, true hyperthyroidism usually requires ongoing monitoring and treatment long after delivery. Assuming it will resolve spontaneously is scientifically inaccurate and potentially dangerous for the mother.

Choice D rationale

Monitoring thyroid-stimulating hormone (TSH) and free T4 levels twice per month is generally excessive for a stable client. The standard of care typically involves testing every 2 to 4 weeks initially, then moving to every 4 to 6 weeks once the client is euthyroid. Normal TSH levels in pregnancy are often lower than non-pregnant ranges (0.1 to 2.5 mIU/L in the first trimester). Over-testing can lead to unnecessary medication adjustments and does not follow standard clinical guidelines.